Abstracts Archive - Page 417 of 1683 - ATC Abstracts

2020 American Transplant Congress
The Effect of Desensitization Therapy on Sex Disparity in Living Kidney Transplantation
Y. Kakuta¹, M. Okumi¹, T. Kanzawa¹, K. Unagami², H. Ishida², K. Tanabe¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan, ²Organ Transplant Medicine, Tokyo Women's Medical University, Tokyo, Japan
*Purpose: Sex- and gender-based disparities which have shown women to have lower access to kidney transplantation have been reported. In living kidney transplantation (LKT), pregnancy-related…
2020 American Transplant Congress
Effect of Simultaneous Presence of Anti-Blood Group A/B and -HLA Antibodies on Clinical Outcomes in Kidney Transplantation Across Positive Crossmatch: A Nationwide Cohort Study
H. Kwon, Y. Ko, D. Han
Department of General Surgery, Asan Medical Center, Seoul, Korea, Republic of
*Purpose: ABO-incompatible (ABOi) and positive crossmatch (XM) kidney transplantation (KT) have been considered immunologically challenging. The present study analyzed the clinical outcomes in XM positive…
2020 American Transplant Congress
Belatacept in Kidney Transplant Recipients with Previous Non-Renal Solid Organ Transplants
O. Cristea, C. Larsen, I. Badell
Emory Transplant Center, Emory University School of Medicine, Atlanta, GA
*Purpose: Selective co-stimulatory blockade with belatacept has demonstrated long-term benefits in renal transplantation, with improved glomerular filtration rate and decreased risk of death and graft…
2020 American Transplant Congress
Recurrence of Igg3Lambda Restricted Cryoglobulinemic Glomerulonephritis in a Renal Allograft: Resolution after Daratumumab Treatment
S. C. Jordan, R. Vescio, J. Hou, N. Ammerman, R. Najjar, S. Sethi, E. Huang, A. Peng, A. Vo
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: C3GN encompasses a group of renal diseases often associated with paraproteinemias. Recurrence in renal allografts is reported. Currently, there are no effective or curative…
2020 American Transplant Congress
CMV, EBV and BKV Viremia Rate Varied Depending on the Timing of Conversion to Belatacept (BLT)- from Calcineurin Inhibitor (CNI)-Based Immunosuppression and HLA-Sensitization (HS) Status in Kidney Transplant Patients (KTx Pts)
B. Shin, N. Ammerman, A. Vo, S. C. Jordan, M. Toyoda, S. Sethi
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Viral infections (VI) represent significant morbidity and mortality factors for KTx Pts. We previously showed more VI in BLT-treated Pts compared with CNI Pts…
2020 American Transplant Congress
Minor Negative Effects of Calcineurin Inhibitor Based Immunosuppression on Pregnancy Outcomes after Renal Transplantation in the Netherlands
L. M. Koenjer¹, J. R. Meinderts², A. T. Lely³, M. F. de Jong², O. W. van der Heijden¹, R. G. van der Molen⁴, H. W. van Hamersvelt⁵
¹Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, Netherlands, ²Nephrology, University Medical Center Groningen, Groningen, Netherlands, ³Obstetrics and Gynaecology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Immunology, Radboud University Medical Centre, Nijmegen, Netherlands, ⁵Nephrology, Radboud University Medical Centre, Nijmegen, Netherlands
*Purpose: Pregnancies after renal transplantation became more frequent over the past years, also in patients with compromised renal function. Immunosuppression may influence pregnancy outcome. It…
2020 American Transplant Congress
Liver Transplantation with Grafts from Super Obese Donors with a BMI>50
P. Vargas¹, J. M. Cullen¹, P. Northup², J. Oberholzer¹, S. Pelletier¹, N. Goldaracena¹
¹Department of Surgery, Division of Transplantation, University of Virginia Health System, Charlottesville, VA, ²Department of Medicine-Gastroenterology, University of Virginia Health System, Charlottesville, VA
*Purpose: Organ shortage is aggravated by an obesity epidemic. There is limited data on liver transplant (LT) outcomes from liver grafts originating from super obese…
2020 American Transplant Congress
Marginal Not So Marginal Anymore: Time for New Definitions for “Marginal” Allografts in Liver Transplantation?
T. Zhang¹, J. Dunson¹, F. Kanwal², T. Galvan², J. Vierling², C. O'Mahony², J. Goss², A. Rana²
¹Medical Student, Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, TX
*Purpose: We examined time trends in the outcomes of patients who received marginal liver allografts defined on the basis of the Donor Risk Index [DRI]…
2020 American Transplant Congress
Impact of a Pharmacist Led Outpatient Tacrolimus Monitoring Protocol in Renal Transplant Recipients
K. L. Owen, M. Palettas, H. Winters, T. E. Pesavento, A. Rajab, O. Witkowsky
Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: The purpose of this study is to compare the time within therapeutic range (TTR) of tacrolimus (TAC) before and after the initiation of a…
2020 American Transplant Congress
De Novo Dosing and Trough Attainment Trends of Extended-Release Tacrolimus in the Absence of Dose Adjustments
M. J. Moritz¹, D. R. Stevens², U. Meier-Kriesche², T. A. Horwedel²
¹Department of Surgery, Lehigh Valley Health Network, Allentown, PA, ²Veloxis Pharmaceuticals, Cary, NC
*Purpose: Initial dosing of tacrolimus extended-release tablets (LCPT) was 0.17 mg/kg/day in the pivotal trial in de novo kidney transplant recipients. Dosing subsequent to the…